Tyrosine kinase gene fusions in cancer: Translating mechanisms into targeted therapies

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 2, 2012, Pages 237-248

  Medves, Sandrine ^a   Demoulin, Jean Baptiste ^a  

^a DE DUVE INSTITUTE   (Belgium)

Author keywords

BCR ABL; Chromosomal translocations; Kinase inhibitors; Receptor tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; CRIZOTINIB; IMATINIB; MICRORNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

DRUG ANTAGONISM; GENE FUSION; GENETICS; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

FUSION PROTEINS, BCR-ABL; GENE FUSION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84856323402     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01415.x     Document Type: Review

References (115)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5: 172-83.
2. Toffalini F, Demoulin JB. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood. 2010; 116: 2429-37.
3. Lacronique V, Boureux A, Valle VD, et al A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997; 278: 1309-12.
4. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006; 155: 645-53.
5. Kwak EL, Bang YJ, Camidge DR, et al Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-703.
6. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer. 2011.
7. Novo FJ, de Mendibil IO, Vizmanos JL. TICdb: a collection of gene-mapped translocation breakpoints in cancer. BMC Genomics. 2007; 8: 33; doi:.
8. Lacronique V, Boureux A, Monni R, et al Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000; 95: 2076-83.
9. Lierman E, Van Miegroet H, Beullens E, et al Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. Haematologica. 2009; 94: 1440-4.
10. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008; 68: 3077-80; discussion 80.
11. Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2009; 145: 581-97.
12. Chan WW, Wise SC, Kaufman MD, et al Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011; 19: 556-68.
13. David M, Cross NC, Burgstaller S, et al Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2007; 109: 61-4.
14. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011; 18: 105-10.
15. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010; 18: 548-51.
16. Chapman PB, Hauschild A, Robert C, et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-16.
17. Tsai J, Lee JT, Wang W, et al Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008; 105: 3041-6.
18. Cools J, DeAngelo DJ, Gotlib J, et al A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348: 1201-14.
19. Gandhi M, Dillon LW, Pramanik S, et al DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene. 29: 2272-80.
20. Burrow AA, Williams LE, Pierce LC, et al Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics. 2009; 10: 59; doi:.
21. Novo FJ, Vizmanos JL. Chromosome translocations in cancer: computational evidence for the random generation of double-strand breaks. Trends Genet. 2006; 22: 193-6.
22. Erben P, Gosenca D, Muller MC, et al Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica. 2010; 95: 738-44.
23. Koschmieder S, Gottgens B, Zhang P, et al Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005; 105: 324-34.
24. Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008; 13: 496-506.
25. Futami M, Hatano T, Soda Y, et al RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells. Leukemia. 2008; 22: 1131-8.
26. Koldehoff M, Kordelas L, Beelen DW, et al Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica. 2010; 95: 388-97.
27. Zheng X, Oancea C, Henschler R, et al Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One. 2009; 4: e7661.
28. Medves S, Duhoux FP, Ferrant A, et al KANK1, a candidate tumour suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia. 2010; 24: 1052-5.
29. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger D, de Knegt Y, et al Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene. 2005; 24: 4129-37.
30. Griesinger F, Janke A, Podleschny M, et al Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br J Haematol. 2002; 119: 454-8.
31. Vu HA, Xinh PT, Masuda M, et al FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia. 2006; 20: 1414-21.
32. Golub TR, Goga A, Barker GF, et al Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996; 16: 4107-16.
33. Tognon CE, Mackereth CD, Somasiri AM, et al Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity. Mol Cell Biol. 2004; 24: 4636-50.
34. Jousset C, Carron C, Boureux A, et al A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 1997; 16: 69-82.
35. De Keersmaecker K, Graux C, Odero MD, et al Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005; 105: 4849-52.
36. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993; 13: 7587-95.
37. McWhirter JR, Wang JY. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene. 1997; 15: 1625-34.
38. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003; 12: 27-37.
39. He Y, Wertheim JA, Xu L, et al The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 2002; 99: 2957-68.
40. Mian AA, Oancea C, Zhao Z, et al Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia. 2009; 23: 2242-7.
41. Ross TS, Gilliland DG. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem. 1999; 274: 22328-36.
42. Medves S, Noel LA, Montano-Almendras CP, et al Multiple oligomerization domains of KANK1-PDGFRB are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica. 2011; 96; in press: doi:.
43. Baumann H, Kunapuli P, Tracy E, et al The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors. J Biol Chem. 2003; 278: 16198-208.
44. Zhao X, Ghaffari S, Lodish H, et al Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002; 9: 117-20.
45. De Keersmaecker K, Rocnik JL, Bernad R, et al Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol Cell. 2008; 31: 134-42.
46. Lelievre H, Chevrier V, Tassin AM, et al Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome. Mol Cancer. 2008; 7: 30; doi:.
47. Mikolajka A, Yan X, Popowicz GM, et al Structure of the N-terminal domain of the FOP (FGFR1OP) protein and implications for its dimerization and centrosomal localization. J Mol Biol. 2006; 359: 863-75.
48. Rigby S, Huang Y, Streubel B, et al The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation. J Biol Chem. 2009; 284: 26871-81.
49. Pechloff K, Holch J, Ferch U, et al The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med. 2010; 207: 1031-44.
50. Tort F, Pinyol M, Pulford K, et al Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest. 2001; 81: 419-26.
51. Touriol C, Greenland C, Lamant L, et al Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood. 2000; 95: 3204-7.
52. Constantinescu SN, Huang LJ, Nam H, et al The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell. 2001; 7: 377-85.
53. Bell CA, Tynan JA, Hart KC, et al Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell. 2000; 11: 3589-99.
54. Toffalini F, Hellberg C, Demoulin JB. Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. J Biol Chem. 2010; 285: 12268-78.
55. Griffith J, Black J, Faerman C, et al The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004; 13: 169-78.
56. Stover EH, Chen J, Folens C, et al Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA. 2006; 103: 8078-83.
57. Lahortiga I, Akin C, Cools J, et al Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica. 2008; 93: 49-56.
58. Vu HA, Xinh PT, Kano Y, et al The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation. Biochem Biophys Res Commun. 2009; 383: 308-13.
59. Chiara F, Bishayee S, Heldin CH, et al Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail. J Biol Chem. 2004; 279: 19732-8.
60. +-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF. Biochem J. 2003; 376: 505-10.
61. Hantschel O, Nagar B, Guettler S, et al A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 2003; 112: 845-57.
62. Zhang J, Adrian FJ, Jahnke W, et al Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010; 463: 501-6.
63. Duhoux FP, Auger N, De Wilde S, et al The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias. Leuk Res. 2011; 35: e114-7.
64. Roumiantsev S, de Aos IE, Varticovski L, et al The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 2001; 97: 4-13.
65. Zhang X, Wong R, Hao SX, et al The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood. 2001; 97: 277-87.
66. Thai M, Ting PY, McLaughlin J, et al ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 2011; 25: 290-300.
67. Morikawa J, Li H, Kim S, et al Identification of signature genes by microarray for acute myeloid leukemia without maturation and acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RARalpha). Int J Oncol. 2003; 23: 617-25.
68. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008; 19: 385-93.
69. Van Roosbroeck K, Cox L, Tousseyn T, et al JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood. 2011; 117: 4056-64.
70. Hazlehurst LA, Bewry NN, Nair RR, et al Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control. 2009; 16: 100-7.
71. Turner SD, Alexander DR. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells. Leukemia. 2006; 20: 572-82.
72. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004; 22: 247-306.
73. Voss J, Posern G, Hannemann JR, et al The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene. 2000; 19: 1684-90.
74. De Keersmaecker K, Versele M, Cools J, et al Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia. 2008; 22: 2208-16.
75. Toffalini F, Kallin A, Vandenberghe P, et al The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica. 2009; 94: 1085-93.
76. Essaghir A, Toffalini F, Knoops L, et al Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res. 2010; 38: e120.
77. Palmer RH, Vernersson E, Grabbe C, et al Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009; 420: 345-61.
78. Wilbanks AM, Mahajan S, Frank DA, et al TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol. 2000; 28: 584-93.
79. Cain JA, Xiang Z, O'Neal J, et al Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood. 2007; 109: 3906-14.
80. Hoelbl A, Schuster C, Kovacic B, et al Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010; 2: 98-110.
81. Buitenhuis M, Verhagen LP, Cools J, et al Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer research. 2007; 67: 3759-66.
82. Heath C, Cross NC. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. J Biol Chem. 2004; 279: 6666-73.
83. Pendergast AM, Quilliam LA, Cripe LD, et al BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993; 75: 175-85.
84. Puil L, Liu J, Gish G, et al Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994; 13: 764-73.
85. Zebedin E, Simma O, Schuster C, et al Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumour surveillance. Blood. 2008; 112: 4655-64.
86. Sattler M, Mohi MG, Pride YB, et al Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002; 1: 479-92.
87. Nguyen TK, Rahmani M, Harada H, et al MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood. 2007; 109: 4006-15.
88. Sjoblom T, Boureux A, Ronnstrand L, et al Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein. Oncogene. 1999; 18: 7055-62.
89. Goss VL, Lee KA, Moritz A, et al A common phosphotyrosine signature for the Bcr-Abl kinase. Blood. 2006; 107: 4888-97.
90. Kunapuli P, Somerville R, Still IH, et al ZNF198 protein, involved in rearrangement in myeloproliferative disease, forms complexes with the DNA repair-associated HHR6A/6B and RAD18 proteins. Oncogene. 2003; 22: 3417-23.
91. Kunapuli P, Kasyapa CS, Chin SF, et al ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML. Exp Cell Res. 2006; 312: 3739-51.
92. Hosoya N, Qiao Y, Hangaishi A, et al Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes Chromosomes Cancer. 2005; 42: 269-79.
93. Armstrong F, Duplantier MM, Trempat P, et al Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004; 23: 6071-82.
94. Armstrong F, Lamant L, Hieblot C, et al TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer. 2007; 43: 640-6.
95. Kasyapa CS, Kunapuli P, Cowell JK. HSPA1A is an important regulator of the stability and function of ZNF198 and its oncogenic derivative, ZNF198-FGFR1. J Cell Biochem. 2007; 102: 1308-17.
96. Barnes DJ, Schultheis B, Adedeji S, et al Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005; 24: 6432-40.
97. Mao JH, Sun XY, Liu JX, et al As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 2010; 107: 21683-8.
98. Mak HH, Peschard P, Lin T, et al Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene. 2007; 26: 7213-21.
99. Tsukahara F, Maru Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood. 2010; 116: 3582-92.
100. Bonvini P, Gastaldi T, Falini B, et al Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 2002; 62: 1559-66.
101. Bonvini P, Dalla Rosa H, Vignes N, et al Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res. 2004; 64: 3256-64.
102. Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol. 2010; 14: 412-20.
103. Trepel J, Mollapour M, Giaccone G, et al Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10: 537-49.
104. Nguyen TK, Rahmani M, Gao N, et al Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res. 2006; 12: 2239-47.
105. Beck R, Verrax J, Gonze T, et al Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol. 2009; 77: 375-83.
106. Frantsve J, Schwaller J, Sternberg DW, et al Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001; 21: 3547-57.
107. Kamizono S, Hanada T, Yasukawa H, et al The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem. 2001; 276: 12530-8.
108. Cacalano NA, Sanden D, Johnston JA. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol. 2001; 3: 460-5.
109. Sakamoto H, Tsukaguchi T, Hiroshima S, et al CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 19: 679-90.
110. Wasag B, Lierman E, Meeus P, et al The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 2011; 96: 922-6.
111. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007; 110: 3729-34.
112. George P, Bali P, Annavarapu S, et al Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005; 105: 1768-76.
113. Radujkovic A, Schad M, Topaly J, et al Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia. 2005; 19: 1198-206.
114. Tong WG, Estrov Z, Wang Y, et al The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. in press: doi:.
115. Wu LX, Xu JH, Zhang KZ, et al Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia. 2008; 22: 1402-9.